EKIVF yields 3.65% · JNJ yields 2.13%● Live data
📍 EKIVF pulled ahead of the other in Year 1
Combined, EKIVF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EKIVF + JNJ for your $10,000?
Enka Insaat ve Sanayi A.S., together with its subsidiaries, operates as a construction company in Turkey, Russia, Kazakhstan, Georgia, Iraq, and internationally. It operates through four segments: Construction, Rental, Energy, and Trading and Manufacturing. The company engages in the construction of industrial and social buildings, and motorways; construction and operation of natural gas fired electrical energy generation facilities; and investment in and development of real estate properties and shopping malls. It is also involved in the marketing and after-sale service of construction machineries, trucks, industrial products, and spare parts; manufacturing of structural steel works; installation and establishment of the technical equipment; and excavation backfilling works and quarrying crushing operation of highway projects. In addition, the company engages in the pile dwelling work; base and superstructure construction; slip form and construction of drilling and ground surveys; organization of conventions and seminars; tour reservations and tickets sales; production of ready-mixed concrete; production and sale of electricity; repair and maintenance of power plants; and provision of architectural design and air transportation services, as well as trading activities. Further, it is involved in various activities, such as material handling and storage systems, auxiliary facilities, water treatment and environmental engineering, infrastructure and construction, control systems, and instrumentation engineering activities. Enka Insaat ve Sanayi A.S. was incorporated in 1957 and is headquartered in Istanbul, Turkey.
Full EKIVF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.